Sutro Biopharma, Inc.'s (NASDAQ:STRO) Latest 24% Decline Adds to One-year Losses, Institutional Investors May Consider Drastic Measures

Yahoo FinanceDec 20 03:31

Sutro Biopharma Is Maintained at Equal-Weight by Wells Fargo

Dow JonesDec 12 04:00 · Ratings

Sutro Biopharma Price Target Cut to $4.00/Share From $5.00 by Wells Fargo

Dow JonesDec 12 04:00 · Ratings

JMP Securities Reiterates Market Outperform on Sutro Biopharma, Maintains $17 Price Target

BenzingaDec 12 01:32 · Ratings

TD Cowen Maintains Sutro Biopharma(STRO.US) With Buy Rating

Futu NewsDec 11 21:33 · Ratings

A Quick Look at Today's Ratings for Sutro Biopharma(STRO.US), With a Forecast Between $4 to $17

Futu NewsDec 11 21:00 · Ratings